je.st
news
Tag: merck announces
Merck Announces Fourth-Quarter and Full-Year 2015 Financial Results
2016-02-03 12:45:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Fourth-Quarter 2015 GAAP EPS was $0.35; Fourth-Quarter Non-GAAP EPS was $0.93, an Increase of 7 Percent; Full-Year 2015 GAAP EPS was $1.56; Full-Year 2015 Non-GAAP EPS was $3.59, an Increase of 3 Percent Fourth-Quarter 2015 Worldwide Sales Were $10.2 Billion, a Decrease of 3 Percent, Including a 7 Percent Negative Impact from Foreign Exchange and 3 Percent Net Favorable Impact from Acquisitions and Divestitures Full-Year 2015 Worldwide Sales Were $39.5 Billion, a Decrease of 6 Percent, Reflecting a 6 Percent Negative Impact from Foreign Exchange and a 3 Percent Net Unfavorable Impact from Acquisitions and Divestitures 2016 Financial Outlook Expects Full-Year 2016 GAAP EPS to be Between $1.96 and $2.23; Expects Non-GAAP EPS to be Between $3.60 and $3.75, Including an Approximately 4 Percent Negative Impact from Foreign Exchange Anticipates Full-Year 2016 Worldwide Sales to be Between $38.7 Billion and $40.2 Billion, Including an Approximately 3 Percent Negative Impact from Foreign Exchange Advanced KEYTRUDA Program sBLA Approval for Treatment of Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 Expanded Indication for First-Line Treatment of Patients with Unresectable or Metastatic Melanoma Obtained FDA Approval of ZEPATIER in the Treatment of Chronic Hepatitis C KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2015. The past year was one of considerable progress and execution for Merck, said Kenneth C. Frazier, chairman and chief executive officer, Merck. Im excited by the near-term opportunities, as we continue launching important new products like ZEPATIER and KEYTRUDA while augmenting and advancing our pipeline. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036Steven Cragle, 908-740-1801orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
financial
announces
merck
Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence
2016-01-27 14:30:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. FDA Grants Priority Review with Target Action Date of July 23, 2016 Marketing Authorization Application Also Filed with the European Medicines Agency KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence. The FDA granted Priority Review for bezlotoxumab, with a Prescription Drug User Fee Act (PDUFA) action date of July 23, 2016. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Robert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: application
license
acceptance
prevention
Emulate Announces Expanded Collaboration With Merck To Use Organ-Chips In Drug Discovery And Development Process For Inflammatory Diseases
2016-01-06 06:17:13| drugdiscoveryonline Home Page
Emulate Inc. recently announced an expanded research collaboration with Merck, known as MSD outside the United States and Canada, to deploy Emulate’s Organ-Chips across certain Merck discovery programs to improve models of human inflammatory diseases and better predict the potential human response of therapeutic candidates
Tags: development
process
drug
expanded
Merck Announces Samsung Bioepis Receives Approval of RENFLEXIS (Infliximab), a Biosimilar of Remicade, in Korea
2015-12-07 14:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Samsung Bioepis Second Immunology Biosimilar Approved, to be Commercialized Under Partnership with Merck KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Samsung Bioepis Co., Ltd. has received approval of RENFLEXIS (infliximab), a biosimilar of the immunology medicine Remicade, by the Ministry of Food and Drug Safety (MFDS) in Korea. Merck will commercialize Samsung Bioepis RENFLEXIS in Korea as part of Mercks commercialization partnership with Samsung Bioepis to offer high-quality biosimilar alternatives to existing biologic medicines. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orRobert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: korea
samsung
approval
receives
Merck Announces Increased Quarterly Dividend
2015-11-24 18:35:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has increased the companys quarterly dividend to $0.46 per outstanding share of the companys common stock, up $0.01 from $0.45 per outstanding share paid last quarter. Payment will be made on Jan. 8, 2016, to stockholders of record at the close of business on Dec. 15, 2015. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: increased
quarterly
announces
dividend
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] next »